NEW YORK, NY / ACCESSWIRE / December 8, 2017 / Halozyme Therapuetics and XOMA Corporation both hit brand new highs during intra-day trading yesterday. Halozyme announced a collaboration and license agreement with Alexion Pharmaceuticals while XOMA Corporation announced it has licensed the global development and commercialization rights for XOMA 358 to Rezolute, Inc.

RDI Initiates Coverage on:

Halozyme Therapeutics, Inc.
https://rdinvesting.com/news/?ticker=HALO

XOMA Corporation
https://rdinvesting.com/news/?ticker=XOMA

Halozyme Therapeutics, Inc. shares closed up 4.58% on Thursday on nearly 2.9 million shares traded. The stock hit a new high of $19.58 yesterday after the company announced that it has teamed up with Alexion Pharmaceuticals on a collaboration and license agreement that enables Alexion to use Halozyme's ENHANZE® drug-delivery technology in the development of subcutaneous formulations for their portfolio of products. This is now Halozyme's eight global collaboration and license partner for the ENHANZE technology, and the third partnership formed this year. CEO Dr. Helen Torley commented, "We are delighted to support Alexion's innovative development initiatives focused on improving the lives of patients with rare diseases. ENHANZE has become the industry standard for converting intravenous therapies to a subcutaneous delivery, helping partners and health care providers reduce the treatment burden and administration time for patients."

Access RDI's Halozyme Therapeutics, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=HALO

XOMA Corporation shares closed up 13.39% yesterday on a little over 375,000 shares traded. The stock hit a brand new high of $34.18 during intra-day trading after the company announced that it has licensed the global development and commercialization rights for XOMA 358 to Rezolute, Inc. As per the agreement, XOMA is entitled to receive up to approximately $240 million in exchange for the global XOMA 358 rights. According to the company's press release, "XOMA 358 is a first-in-class fully human antibody that inhibits the effects of elevated insulin (hyperinsulinemia) via allosteric modulation of the insulin receptor." CEO Jim Neal stated, "Out-licensing XOMA 358 is another milestone in executing our strategy to create long-term value for our shareholders. Rezolute's focus on insulin-related conditions makes them an ideal company to continue XOMA 358's clinical development. This license agreement further expands our portfolio of partner-funded programs that have the potential to generate substantial milestone and royalty payments. We welcome Rezolute to our broad portfolio of partners, including Novartis, Five Prime and Nanotherapeutics, who continue the development of our product candidates."

Access RDI's XOMA Corporation Research Report at:
https://rdinvesting.com/news/?ticker=XOMA

Our Actionable Research on Halozyme Therapeutics, Inc. (NASDAQ: HALO) and XOMA Corporation (NASDAQ: XOMA) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com